Scholarlink

Background <p>Angiopoietin-like protein 3 (Angptl3), a factor secreted by the liver, inhibits lipoprotein lipase and other lipases by forming a complex with Angptl4 and 8. However, whether inhibition of Angptl3 can alleviate hepatic lipid accumulation and atherosclerosis remains unclear. Therefore, this study explored the effect of small interfering RNA (siRNA)-based inactivation of Angptl3 on metabolic dysfunction-associated fatty liver disease (MAFLD) and atherosclerosis in male LDLR-deficient hamsters.</p> Methods <p>Recombinant adeno-associated virus serotype 9 (AAV9) encoding Angptl3-siRNA or empty AAV (AAV9-null) were injected into male 4-month-old LDLR<sup>−/−</sup> hamsters via the jugular vein. Subsequently, all hamsters were administered with a 16-week high-fat diet (HFD) feeding to induce atherosclerosis. RT-PCR and pathological analysis were used to investigate the mechanism of hepatic lipid accumulation and detect atherosclerotic plaque formation in the heart and aorta.</p> Results <p>On HFD, Angptl3-siRNA-treated hamsters displayed significantly decreased plasma triglyceride (TG), total cholesterol, high-density lipoprotein-cholesterol, and glucose levels, compared with the AAV9-null hamsters. FPLC analysis further revealed a marked reduction of TG and cholesterol contents in VLDL/LDL fractions. Plasma apolipoprotein analysis showed relatively lower ApoB/ApoE levels and higher ApoA1 levels. Moreover, Angptl3-siRNA markedly accelerated the clearance of triglyceride-rich lipoproteins in LDLR<sup>−/−</sup> hamsters. Consistently, results from hepatic lipid extraction, Oil Red O and Sirius Red staining demonstrated that Angptl3-siRNA reduced hepatic lipid accumulation and ameliorated HFD-induced MAFLD. RT-PCR revealed a dramatic decrease in the expression of <i>Acc1, Fasn, Srebp1c, Cd36, Fatp1, Tgfβ, Cd68</i>, <i>Tnfa</i>, and <i>Col1a1</i> as well as a marked increase in <i>Abcg5, Abcg8, Ppara, and Cpt1</i> expression, which participated in fatty acid synthesis and oxidation, cholesterol synthesis and efflux, inflammation and fibrosis. Pathological analysis indicated that Angptl3-siRNA attenuated the formation of atherosclerotic plaques in the aortic root and aorta when compared with the control group.</p> Conclusions <p>These findings demonstrated that siRNA-based inactivation of Angptl3 alleviated MAFLD and atherosclerosis induced by HFD in LDLR<sup>−/−</sup> hamsters, which further confirmed that inhibition of Angptl3 may provide a novel therapeutic approach for atherosclerosis by reducing hyperlipidemia and hepatic lipid accumulation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SiRNA-based inactivation of Angptl3 alleviates high-fat diet-induced MAFLD and atherosclerosis in LDLR-deficient hamsters

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Xiaohong Zhang,
  • Yufei Han,
  • Liwen Zheng,
  • Xiaokui He,
  • Yungang Pu,
  • Lili Wei,
  • Yuhui Wang,
  • Xunde Xian

摘要

Background

Angiopoietin-like protein 3 (Angptl3), a factor secreted by the liver, inhibits lipoprotein lipase and other lipases by forming a complex with Angptl4 and 8. However, whether inhibition of Angptl3 can alleviate hepatic lipid accumulation and atherosclerosis remains unclear. Therefore, this study explored the effect of small interfering RNA (siRNA)-based inactivation of Angptl3 on metabolic dysfunction-associated fatty liver disease (MAFLD) and atherosclerosis in male LDLR-deficient hamsters.

Methods

Recombinant adeno-associated virus serotype 9 (AAV9) encoding Angptl3-siRNA or empty AAV (AAV9-null) were injected into male 4-month-old LDLR−/− hamsters via the jugular vein. Subsequently, all hamsters were administered with a 16-week high-fat diet (HFD) feeding to induce atherosclerosis. RT-PCR and pathological analysis were used to investigate the mechanism of hepatic lipid accumulation and detect atherosclerotic plaque formation in the heart and aorta.

Results

On HFD, Angptl3-siRNA-treated hamsters displayed significantly decreased plasma triglyceride (TG), total cholesterol, high-density lipoprotein-cholesterol, and glucose levels, compared with the AAV9-null hamsters. FPLC analysis further revealed a marked reduction of TG and cholesterol contents in VLDL/LDL fractions. Plasma apolipoprotein analysis showed relatively lower ApoB/ApoE levels and higher ApoA1 levels. Moreover, Angptl3-siRNA markedly accelerated the clearance of triglyceride-rich lipoproteins in LDLR−/− hamsters. Consistently, results from hepatic lipid extraction, Oil Red O and Sirius Red staining demonstrated that Angptl3-siRNA reduced hepatic lipid accumulation and ameliorated HFD-induced MAFLD. RT-PCR revealed a dramatic decrease in the expression of Acc1, Fasn, Srebp1c, Cd36, Fatp1, Tgfβ, Cd68, Tnfa, and Col1a1 as well as a marked increase in Abcg5, Abcg8, Ppara, and Cpt1 expression, which participated in fatty acid synthesis and oxidation, cholesterol synthesis and efflux, inflammation and fibrosis. Pathological analysis indicated that Angptl3-siRNA attenuated the formation of atherosclerotic plaques in the aortic root and aorta when compared with the control group.

Conclusions

These findings demonstrated that siRNA-based inactivation of Angptl3 alleviated MAFLD and atherosclerosis induced by HFD in LDLR−/− hamsters, which further confirmed that inhibition of Angptl3 may provide a novel therapeutic approach for atherosclerosis by reducing hyperlipidemia and hepatic lipid accumulation.